Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Alternatives for Reducing Chorea in HD (ARC-HD)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Auspex Pharmaceuticals, Inc. ) Identifier:
First received: June 14, 2013
Last updated: December 1, 2016
Last verified: December 2016
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of SD-809 ER in subjects switching from tetrabenazine to SD-809 ER. In addition, the safety and tolerability of long term treatment with SD-809 ER will be assessed in "Switch" subjects as well as "Rollover" subjects completing a randomized, double blind, placebo controlled study of SD-809 ER,

Condition Intervention Phase
Chorea Associated With Huntington Disease
Drug: SD-809
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Long Term Safety Study of SD-809 ER in Patients With Chorea Associated With Huntington Disease

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Overall incidence of adverse events (AEs), serious AEs, severe AEs, drug related AEs, AEs leading to withdrawal [ Time Frame: Duration of study ]
  • Incidence of adverse events (AEs), serious AEs, severe AEs, drug related AEs, AEs leading to withdrawal during the titration period in Rollover subjects [ Time Frame: Up to 8 weeks ]
  • Incidence of adverse events (AEs), serious AEs, severe AEs, drug related AEs, AEs leading to withdrawal during the dose adjustment period in Switch subjects [ Time Frame: Up to 4 weeks ]
  • Incidence of adverse events (AEs), serious AEs, severe AEs, drug related AEs, AEs leading to withdrawal during long term treatment [ Time Frame: From Week 3 to end of study ]

Secondary Outcome Measures:
  • Changes from baseline in clinical laboratory parameters (hematology, chemistry and urinalysis) [ Time Frame: Duration of study ]
  • Changes from baseline in UHDRS, UPDRS (dysarthria), BARS, HADS, ESS, C-SSR, and MoCA [ Time Frame: Duration of study ]
  • Changes from baseline in vital signs [ Time Frame: Duration of study ]
  • Changes from baseline in ECG parameters and abnormal findings [ Time Frame: Duration of study ]
  • Duration of time to achieve stable dosing of SD-809 ER [ Time Frame: Up to 4 weeks ]

Enrollment: 238
Study Start Date: November 2013
Estimated Study Completion Date: October 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Switch Subject Cohort
Switch subjects are those who are currently receiving stable doses of tetrabenazine for treatment of chorea associated with HD and convert to SD-809 ER based on an algorithm designed to achieve comparable exposure to total (α+β)-HTBZ metabolites.
Drug: SD-809
SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
Other Name: deutetrabenazine
Experimental: Rollover Subject Cohort
Rollover subjects are those who have successfully completed Study SD-809-C-15 and are continuing on long-term SD-809 ER after a 1-week wash out period.
Drug: SD-809
SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
Other Name: deutetrabenazine


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject is at least 18 years of age or the age of majority (whichever is older) at Screening.
  2. Subject has been diagnosed with manifest HD, as indicated by characteristic motor exam features, and has a documented expanded CAG repeat (≥ 37) at or before Screening.
  3. Subject meets either of the following:

    • Has successfully completed participation in the First-HD Study (SD-809-C-15) OR
    • Has been receiving an FDA-approved dose of tetrabenazine that has been stable for ≥ 8 weeks before Screening and is providing a therapeutic benefit for control of chorea.
  4. Subject has a Total Functional Capacity (TFC) score ≥ 5 at Screening.
  5. Subject is able to swallow study medication whole.
  6. Subject has provided written, informed consent or, a legally authorized representative (LAR) has provided written informed consent and the subject has provided assent.
  7. Subject has provided a Research Advance Directive.
  8. Female subjects of childbearing potential agree to use an acceptable method of contraception from screening through study completion.
  9. The subject has a reliable caregiver who interacts with the patient on a daily basis, oversees study drug administration, assures attendance at study visits and participates in evaluations, as required.
  10. Subject is able to ambulate without assistance for at least 20 yards (Note: The use of assistive devices (i.e., walker, cane) are permitted during ambulation).
  11. Has sufficient reading skills to comprehend the subject completed rating scales.

Exclusion Criteria:

  1. Subject has a serious untreated or under-treated psychiatric illness, such as depression, at Screening or Baseline.
  2. Subject has active suicidal ideation at Screening or Baseline.
  3. Subject has history of suicidal behavior at Screening or Baseline.
  4. Subject has evidence for depression at Baseline.
  5. Subject has an unstable or serious medical illness at Screening or Baseline.
  6. Subject has received tetrabenazine within 7 days of Baseline (Rollover subjects only).
  7. Subject has received any of the following concomitant medications within 30 days of Screening or Baseline:

    • Antipsychotics
    • Metoclopramide
    • Monoamine oxidase inhibitors (MAOI)
    • Levodopa or dopamine agonists
    • Reserpine
    • Amantadine
    • Memantine (Rollover subjects only)

      • Switch subjects may receive Memantine if on a stable, approved dose for at least 30 days
  8. Subject has significantly impaired swallowing function at Screening or Baseline.
  9. Subject has significantly impaired speaking at Screening or Baseline.
  10. Subject requires treatment with drugs known to prolong the QT interval.
  11. Subject has prolonged QT interval on 12-lead ECG at Screening.
  12. Subject has evidence of hepatic impairment at Screening.
  13. Subject has evidence of significant renal impairment at Screening.
  14. Subject has known allergy to any of the components of study medication.
  15. Subject has participated in an investigational drug or device trial other than SD-809-C-15 within 30 days (or 5 drug half-lives) of Screening, whichever is longer.
  16. Subject is pregnant or breast-feeding at Screening or Baseline.
  17. Subject acknowledges present use of illicit drugs at Screening or Baseline.
  18. Subject has a history of alcohol or substance abuse in the previous 12 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01897896

  Hide Study Locations
United States, Alabama
Teva Investigational Site 057
Birmingham, Alabama, United States
United States, Arizona
Teva Investigational Site 038
Phoenix, Arizona, United States
United States, Arkansas
Teva Investigational Site 298
Fayetteville, Arkansas, United States
United States, Colorado
Teva Investigational Site 052
Englewood, Colorado, United States
United States, District of Columbia
Teva Investigational Site 333
Washington, District of Columbia, United States
United States, Florida
Teva Investigational Site 160
Gainesville, Florida, United States
Teva Investigational Site 014
Miami, Florida, United States
United States, Georgia
Teva Investigational Site 032
Atlanta, Georgia, United States
United States, Indiana
Teva Investigational Site 045
Indianapolis, Indiana, United States
United States, Iowa
Teva Investigational Site 024
Iowa City, Iowa, United States
United States, Kansas
Teva Investigational Site 029
Kansas City, Kansas, United States
Teva Investigational Site 083
Wichita, Kansas, United States
United States, Kentucky
Teva Investigational Site 087
Louisville, Kentucky, United States
United States, Maryland
Teva Investigational Site 028
Baltimore, Maryland, United States
United States, Massachusetts
Teva Investigational Site 040
Boston, Massachusetts, United States
United States, Missouri
Teva Investigational Site 027
St. Louis, Missouri, United States
United States, Nevada
Teva Investigational Site 194
Las Vegas, Nevada, United States
United States, New Jersey
Teva Investigational Site 328
Camden, New Jersey, United States
Teva Investigational Site 026
New Brunswick, New Jersey, United States
United States, New York
Teva Investigational Site 037
Albany, New York, United States
Teva Investigational Site 002
New York, New York, United States
Teva Investigational Site 342
Patchogue, New York, United States
United States, North Carolina
Teva Investigational Site 119
Durham, North Carolina, United States
United States, Ohio
Teva Investigational Site 089
Cincinnati, Ohio, United States
Teva Investigational Site 020
Columbus, Ohio, United States
Teva Investigational Site 093
Toledo, Ohio, United States
United States, Oklahoma
Teva Investigational Site 341
Tulsa, Oklahoma, United States
United States, Tennessee
Teva Investigational Site 031
Nashville, Tennessee, United States
United States, Texas
Teva Investigational Site 007
Houston, Texas, United States
Teva Investigational Site 199
Houston, Texas, United States
United States, Utah
Teva Investigational Site 100
Salt Lake City, Utah, United States
United States, Vermont
Teva Investigational Site 137
Burlington, Vermont, United States
United States, Washington
Teva Investigational Site 220
Kirkland, Washington, United States
Teva Investigational Site 096
Seattle, Washington, United States
United States, Wisconsin
Teva Investigational Site 104
Milwaukee, Wisconsin, United States
Teva Investigational Site 144
Kew Vic, Australia
Teva Investigational Site 054
Sydney, Australia
Teva Investigational Site 098
Montreal, Canada
Teva Investigational Site 231
Ottawa, Canada
Teva Investigational Site 300
Ottawa, Canada
Sponsors and Collaborators
Auspex Pharmaceuticals, Inc.
Study Director: Teva Medical Expert, MD TEVA
  More Information

Responsible Party: Auspex Pharmaceuticals, Inc. Identifier: NCT01897896     History of Changes
Other Study ID Numbers: SD-809-C-16
Study First Received: June 14, 2013
Last Updated: December 1, 2016

Keywords provided by Teva Pharmaceutical Industries:
Huntington Disease

Additional relevant MeSH terms:
Huntington Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Cognition Disorders
Neurocognitive Disorders
Mental Disorders
Neurologic Manifestations
Signs and Symptoms processed this record on May 23, 2017